Investment
Features
FeesSafety
Academy
More
Pluang+

BofA keeps 'buy' on Corteva, citing new products and tighter 2027 ag markets boosting growth outlook.

Analyst Insights
05 Oct 2026
Proactive Investors
View Source
Bullish
BofA keeps 'buy' on Corteva, citing new products and tighter 2027 ag markets boosting growth outlook.

Bank of America maintains a 'buy' rating on Corteva Inc with an $18 price target, highlighting new product launches and tighter agricultural markets in 2027 as growth drivers. Corteva recently spun off its seed business, focusing on crop protection, with expected revenue and EBITDA growth by 2029. The analyst is cautiously optimistic about Corteva's product pipeline offsetting legacy sales declines amid competitive pressures. Improved grain market conditions in 2027 and ongoing product innovation are seen as key supports for the company’s outlook.

Corteva's outlook amid innovation and market pressures is the focus, with Pluang providing a snapshot of the Basic Materials sector. As of Oct 06, 2026 01:41 WIB, 29 of 38 priced US Basic Materials stocks rose while 9 fell. Notable prices include Kinross Gold Corporation (KGC) at USD 23.80 with a 1-day change of -1.10% and a typical hold time of 52 days, DuPont de Nemours Inc (DD) at USD 131.36 up 1.06%, and BHP Billiton Limited (BHP) at USD 86.98 also up 1.06%, with a typical hold time of 142 days.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
1 hour ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
2 hours ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
3 hours ago
SPYM ETF charges less than VOO for S&P 500 exposure but tracks multiple indexes historically.

SPYM ETF charges less than VOO for S&P 500 exposure but tracks multiple indexes historically.

The SPDR Portfolio S&P 500 ETF (SPYM) charges a lower fee of 0.02% compared to Vanguard's VOO at 0.03%, making it slightly cheaper for investors seeking S&P 500 exposure. However, SPYM's long-term performance record is based on four different indexes...

Market News
Neutral
4 hours ago
Newfoundland Discovery Corp. rebrands as Genesis Goldfields Corp. with new ticker GGF on CSE.

Newfoundland Discovery Corp. rebrands as Genesis Goldfields Corp. with new ticker GGF on CSE.

Newfoundland Discovery Corp., a Canadian gold exploration company focused on Angola, has changed its name to Genesis Goldfields Corp. Along with the rebranding, its trading symbol on the Canadian Securities Exchange will change from NEWD to GGF start...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App